A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
Olszewski A, Huntington S, Ollila T, Pelcovits A, McMahon J, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2023, 41: tps7588-tps7588. DOI: 10.1200/jco.2023.41.16_suppl.tps7588.Peer-Reviewed Original ResearchMarginal zone lymphomaCytokine release syndromeFirst-line therapyCR rateT cell-engaging bispecific antibodiesFirst-line systemic therapyCytotoxic T cell responsesLow-dose lenalidomideComplete response rateFirst-line treatmentLines of therapyPhase 2 trialT-cell depletionT cell immunityT cell responsesHost immune environmentRate of progressionRates of toxicityNovel therapeutic approachesHigh-burden diseasesImmunosuppressive modalitiesRefractory FLRelease syndromeStable diseaseStudy therapy